VSV-IFNβ-NIS

BIOLOGICAL2 trials

Sponsors

Vyriad, Inc.

Conditions

Malignant Solid TumourNeuroendocrine CarcinomaNon Small Cell Lung CancerRenal Cell Carcinoma (RCC)Solid Tumor

Phase 1

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

CompletedNCT02923466

Vyriad, Inc.Malignant Solid Tumour

Start: 2017-04-17End: 2022-04-22Updated: 2022-04-27

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Active, not recruitingNCT03647163

Vyriad, Inc.Neuroendocrine Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) +1

Start: 2019-04-09End: 2025-09-30Updated: 2025-09-16

Related Papers

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.

Journal of Clinical Oncology2024-01-201 citations

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.

Journal of Clinical Oncology2023-06-011 citations

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.

Journal of Clinical Oncology2023-01-244 citations

505 Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1–2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations

Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.

Journal of Clinical Oncology2020-05-2013 citations

VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Annals of Oncology2018-10-012 citations

Tracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy

Annals of Oncology2018-10-011 citations